Crealta Pharmaceuticals, a startup backed by investment firm GTCR, unveiled its first significant deal Dec. 11, when it acquired gout drug Krystexxa (pegloticase) and other assets of troubled Savient Pharmaceuticals Inc.
Crealta will pay $120.4 million for Savient’s pharmaceutical assets through an agreement brokered at auction in U.S. Bankruptcy Court. In...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?